| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| JS-015 | JS-015 | Phase 2 Clinical | Shanghai Junshi Biological Engineering Co Ltd | Colorectal Neoplasms; Neoplasms; Solid tumours | Details |
| AGA-2115 | AGA2115; AGA-2115 | Phase 2 Clinical | Angitia Biopharmaceuticals (Guangzhou) Ltd | Osteogenesis Imperfecta | Details |
| AGA-2118 | AGA-2118 | Phase 2 Clinical | Angitia Biomedicines Ltd | Osteoporosis; Osteoporosis, Postmenopausal | Details |
| Sirexatamab | DKN-01; LY-2812176 | Phase 2 Clinical | Eli Lilly And Company | Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinosarcoma; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Gallbladder Neoplasms; Liver Neoplasms; Multiple Myeloma; Ovarian Neoplasms; Prostatic Neoplasms; Solid tumours; Stomach Neoplasms; Uterine Neoplasms | Details |